A Phase 2/3 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 93 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-07.
Sponsored by Pfizer · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.
Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 2/3, and was the 7th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States, Israel
Ages 18+
Pfizer · Sites in India
Ages 18+
Pfizer · Sites in United States, Israel
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 16 · Phase 4 9
First in 2011; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,590 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 618 across the 32 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 8th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 2/3, and was the 11th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing rimegepant in Migraine Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07918053Chinese PLA General HospitalA Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals | 2027-06 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing rimegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DBT Phase (Weeks 1 through 12): Participants received a single oral dose of rimegepant 75 mg tablet every other day (EOD) for 12 weeks. OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (as needed \[PRN\] dosing). After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation.
Drug: Rimegepant
DBT Phase (Weeks 1 through 12): Participants received a single oral dose of placebo matching to rimegepant tablet EOD for 12 weeks. OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (PRN dosing). After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation.
Drug: Rimegepant · Drug: Placebo
Rimegepant 75 mg tablet EOD
Also known as: BHV-3000
Placebo tablet to match rimegepant tablet EOD
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase
A migraine day: any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache: a migraine with or without aura, lasting for ≥30 minutes, and meeting at least 1 of the following criteria (a and/or b): a) ≥2 of the following: unilateral location, pulsating quality, moderate to severe pain intensity, aggravation by or causing avoidance of routine physical activity; b) ≥1 of the following: nausea and/or vomiting, photophobia, and phonophobia. If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the last 4 weeks of the DBT phase (Weeks 9 to 12) minus number of monthly migraine days during the OP.
Time frame: OP and Weeks 9 to 12 of the DBT phase
Number of Participants Who Had ≥ 50% Reduction in Moderate or Severe Migraine Days Per Month in the Last 4 Weeks of the DBT Phase
A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. A moderate or severe migraine day was a migraine day of moderate or severe pain intensity. Months were defined as 28-day intervals. A reduction of at least 50% in the mean number of moderate or severe monthly migraine days was determined if the number of moderate or severe monthly migraine days in the last 4 weeks of the DBT (Weeks 9 to 12) was less than or equal to half (50%) of the number of moderate or severe monthly migraine days in the OP.
Time frame: OP and Weeks 9 to 12 of the DBT phase
Change From Baseline in the Mean Number of Migraine Days Per Month Over the Entire Course of the DBT Phase
A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the DBT phase (Weeks 1 to 12) minus the number of monthly migraine days during the OP.
Time frame: OP and Weeks 1 to 12 of the DBT phase
Frequency of Use of Rescue Medication Days Per Month in the Last Month of the DBT Phase
A rescue medication day was a day on which the participant took triptan, ergotamine, or other permitted medication to acutely treat headache or aura. Months were defined as 28-day intervals.
Time frame: Weeks 9 to 12 of the DBT phase
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the First Month of the DBT Phase
A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the first 4 weeks of the DBT phase (Weeks 1 to 4) minus the number of monthly migraine days during the OP.
Time frame: OP and Weeks 1 to 4 of the DBT phase
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation in the DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition on-treatment in a patient or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received rimegepant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
Time frame: Weeks 1 to 12 of the DBT phase
Number of Participants With AEs, SAEs, AEs Leading to Study Drug Discontinuation in the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition on-treatment in a patient or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received rimegepant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
Time frame: OLE Phase (Weeks 13 through 64)
Number of Participants With Clinically Significant Laboratory Abnormalities in the DBT Phase
Clinically significant laboratory abnormalities were defined as Grade 3 to 4 laboratory test results according to numeric laboratory test criteria found in Common Technical Criteria for Adverse Events (CTCAE) Version 5.0 (2017) if available; otherwise, according to Division of Acquired Immune Deficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, LDL-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in the DBT phase to be included for a given parameter.
Time frame: Weeks 1 to 12 of the DBT phase
Number of Participants With Clinically Significant Laboratory Abnormalities in the OLE Phase
Clinically significant laboratory abnormalities were defined as Grade 3 to 4 laboratory test results according to numeric laboratory test criteria found in CTCAE Version 5.0 (2017) if available; otherwise, according to DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, LDL-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in the OLE phase to be included for a given parameter.
Time frame: OLE Phase (Weeks 13 through 64)
Number of Participants With Elevations of AST or ALT > 3 x Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) > 2 x ULN During the DBT Phase
Elevations of AST or ALT \> 3 x ULN concurrent with TBL \> 2 x ULN were defined as elevations on the same collection date. Participants must have had a non-missing AST, ALT, or TBL measurement in the OLE phase to be included.
Time frame: Weeks 1 to 12 of the DBT phase
Percentage of Participants With Elevations of AST or ALT > 3 x ULN Concurrent With TBL > 2 x ULN During the OLE Phase
Elevations of AST or ALT \> 3 x ULN concurrent with TBL \> 2 x ULN were defined as elevations on the same collection date. Participants must have had a non-missing AST, ALT, or TBL measurement in the DBT phase to be included.
Time frame: OLE Phase (Weeks 13 through 64)
Number of Participants With Hepatic-related AEs and Hepatic-related AEs Leading to Discontinuation During the DBT Phase
Hepatic AEs were defined as all preferred terms in the DBT phase under the "Hepatic Disorders" Standardized Medical Dictionary (Version 21.1) for Regulatory Activities Query (SMQ), except those preferred terms in the "Congenital, Familial, Neonatal and Genetic Disorders of the Liver" SMQ.
Time frame: Weeks 1 to 12 of the DBT phase
Number of Participants With Hepatic-related AEs and Hepatic-related AEs Leading to Discontinuation During the OLE Phase
Hepatic AEs were defined as all preferred terms in the OLE phase under the "Hepatic Disorders" SMQ, except those preferred terms in the "Congenital, Familial, Neonatal and Genetic Disorders of the Liver" SMQ.
Time frame: OLE Phase (Weeks 13 through 64)
Mean Change From Baseline in the Migraine Specific Quality of Life (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase
The Migraine Specific Quality of Life (MSQoL) is a self-administered, 14-item instrument that has been validated in 3 domains: role restriction, role prevention, and the emotional function. The role function-restrictive domain consists of 7 items that describe how migraine limits one's daily social and work-related activities. Participants respond to items using a 6-point scale: "none of the time," "a little bit of the time," "some of the time," "a good bit of the time," "most of the time," and "all of the time," which are assigned scores of 1 to 6, respectively. Item scores are recoded using (7 - original score). Next, raw dimension scores are computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life. The change from baseline was calculated as the MSQoL restrictive role function domain score at Week 12 of the DBT phase minus the MSQoL restrictive role function domain score at baseline.
Time frame: Baseline, Week 12 of the DBT Phase
Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12 of the DBT Phase
The Migraine Disability Assessment (MIDAS) is a retrospective, self-administered, 5-item questionnaire that measures headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provide the number of missed work or school days; missed household chores days; missed social or leisure activity days; and days at work or school, and separately at home, where productivity was reduced by half or more in the last 3 months (scale: 0 - 90 for each of 5 subscales). The 5 subscale scores are summed to compute the MIDAS total score (scale: 0 - 450). Lower scores indicate less headache-related disability. The change from baseline was calculated as the MIDAS total score at Week 12 of the DBT phase minus the MIDAS total score at baseline.
Time frame: Baseline, Week 12 of the DBT Phase
The study was conducted at 92 sites in the United States.
| Milestone | DBT Rimegepant/OL Rimegepant | DBT Placebo/OL Rimegepant |
|---|---|---|
| Started | 370 | 371 |
| Completed | 316 | 310 |
| Not completed | 54 | 61 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Eligibility failure due to baseline laboratory values | 8 | 13 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Lost to follow-up | 19 | 12 |
| Withdrew: Non-compliance | 6 | 5 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol deviation | 4 | 5 |
| Withdrew: Withdrawal by subject | 11 | 22 |
| Milestone | DBT Rimegepant/OL Rimegepant | DBT Placebo/OL Rimegepant |
|---|---|---|
| Started | 302 | 301 |
| Completed | 209 | 219 |
| Not completed | 93 | 82 |
| Withdrew: Adverse event | 10 | 9 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Extension phase eligibility failure due to week 12 laboratory values | 2 | 0 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Lost to follow-up | 19 | 13 |
| Withdrew: Non-compliance | 15 | 14 |
| Withdrew: Physician decision | 9 | 9 |
| Withdrew: Pregnancy | 2 | 2 |
| Withdrew: Protocol deviation | 2 | 3 |
| Withdrew: Sponsor recommendation | 1 | 0 |
| Withdrew: Withdrawal by subject | 29 | 28 |
| Withdrew: Other than specified | 1 | 1 |
| Milestone | DBT Rimegepant/OL Rimegepant | DBT Placebo/OL Rimegepant |
|---|---|---|
| Started | 332 | 336 |
| Completed | 267 | 274 |
| Not completed | 65 | 62 |
| Withdrew: Not reported | 49 | 48 |
| Withdrew: Lost to follow-up | 10 | 6 |
| Withdrew: Non-compliance | 2 | 1 |
| Withdrew: Withdrawal by subject | 4 | 7 |
A migraine day: any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache: a migraine with or without aura, lasting for ≥30 minutes, and meeting at least 1 of the following criteria (a and/or b): a) ≥2 of the following: unilateral location, pulsating quality, moderate to severe pain intensity, aggravation by or causing avoidance of routine physical activity; b) ≥1 of the following: nausea and/or vomiting, photophobia, and phonophobia. If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the last 4 weeks of the DBT phase (Weeks 9 to 12) minus number of monthly migraine days during the OP.
| Total Migraine Days per Month | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase | -4.3 (-4.83 to -3.87) | -3.5 (-4 to -3.04) |
A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. A moderate or severe migraine day was a migraine day of moderate or severe pain intensity. Months were defined as 28-day intervals. A reduction of at least 50% in the mean number of moderate or severe monthly migraine days was determined if the number of moderate or severe monthly migraine days in the last 4 weeks of the DBT (Weeks 9 to 12) was less than or equal to half (50%) of the number of moderate or severe monthly migraine days in the OP.
| percentage of participants | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Number of Participants Who Had ≥ 50% Reduction in Moderate or Severe Migraine Days Per Month in the Last 4 Weeks of the DBT Phase | 49.1 (43.9 to 54.3) | 41.5 (36.3 to 46.7) |
A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the DBT phase (Weeks 1 to 12) minus the number of monthly migraine days during the OP.
| Total Migraine Days per Month | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Change From Baseline in the Mean Number of Migraine Days Per Month Over the Entire Course of the DBT Phase | -3.6 (-3.97 to -3.17) | -2.7 (-3.14 to -2.34) |
A rescue medication day was a day on which the participant took triptan, ergotamine, or other permitted medication to acutely treat headache or aura. Months were defined as 28-day intervals.
| rescue medication Days per Month | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Frequency of Use of Rescue Medication Days Per Month in the Last Month of the DBT Phase | 3.7 (3.29 to 4.15) | 4.0 (3.53 to 4.39) |
A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the first 4 weeks of the DBT phase (Weeks 1 to 4) minus the number of monthly migraine days during the OP.
| migraine days per month | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Change From Baseline in the Mean Number of Total Migraine Days Per Month in the First Month of the DBT Phase | -2.9 (-3.32 to -2.46) | -1.7 (-2.15 to -1.29) |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition on-treatment in a patient or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received rimegepant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
| Participants | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| AEs | 133 | 133 |
| SAEs | 3 | 4 |
| AEs leading to study drug discontinuation | 7 | 4 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition on-treatment in a patient or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received rimegepant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
| Participants | DBT Rimegepant/OL Rimegepant | DBT Placebo/OL Rimegepant |
|---|---|---|
| AEs | 150 | 162 |
| SAEs | 7 | 6 |
| AEs leading to study drug discontinuation | 9 | 8 |
Clinically significant laboratory abnormalities were defined as Grade 3 to 4 laboratory test results according to numeric laboratory test criteria found in Common Technical Criteria for Adverse Events (CTCAE) Version 5.0 (2017) if available; otherwise, according to Division of Acquired Immune Deficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, LDL-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in the DBT phase to be included for a given parameter.
| Participants | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Eosinophils | 0 | 0 |
| Hemoglobin | 0 | 1 |
| Lymphocytes, high | 0 | 0 |
| Lymphocytes, low | 0 | 0 |
| Neutrophils | 4 | 2 |
| Platelets | 1 | 0 |
| White Blood Cells | 1 | 0 |
| Alanine Aminotransferase (ALT) | 1 | 0 |
| Aspartate Aminotransferase (AST) | 1 | 0 |
| Albumin | 0 | 0 |
| Alkaline Phosphatase | 0 | 0 |
| Bicarbonate | 0 | 0 |
| Bilirubin | 0 | 0 |
| Calcium, high | 0 | 0 |
| Calcium, low | 0 | 0 |
| Cholesterol | 0 | 0 |
| Creatine Kinase | 4 | 4 |
| Creatinine | 0 | 0 |
| Glucose, high | 0 | 0 |
| Glucose, low | 0 | 0 |
| LDL-cholesterol | 2 | 0 |
| LDL-cholesterol, fasting | 0 | 0 |
| LDL-cholesterol, not fasting | 2 | 0 |
| Lactate Dehydrogenase | 0 | 0 |
| Potassium, high | 1 | 2 |
| Potassium, low | 0 | 0 |
| Sodium, high | 0 | 0 |
| Sodium, low | 0 | 0 |
| Triglycerides | 0 | 0 |
| Triglycerides, fasting | 0 | 0 |
| Triglycerides, not fasting | 0 | 0 |
| Uric acid | 0 | 0 |
| Glomerular Filtration Rate, Estimated | 1 | 0 |
| Urine Glucose | 0 | 0 |
| Urine Protein | 1 | 0 |
Clinically significant laboratory abnormalities were defined as Grade 3 to 4 laboratory test results according to numeric laboratory test criteria found in CTCAE Version 5.0 (2017) if available; otherwise, according to DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, LDL-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in the OLE phase to be included for a given parameter.
| Participants | DBT Rimegepant/OL Rimegepant | DBT Placebo/OL Rimegepant |
|---|---|---|
| Eosinophils | 0 | 0 |
| Hemoglobin | 1 | 1 |
| Lymphocytes, high | 0 | 0 |
| Lymphocytes, low | 1 | 0 |
| Neutrophils | 1 | 1 |
| Platelets | 0 | 0 |
| White Blood Cells | 0 | 0 |
| Alanine Aminotransferase (ALT) | 0 | 5 |
| Aspartate Aminotransferase (AST) | 1 | 3 |
| Albumin | 0 | 0 |
| Alkaline Phosphatase | 0 | 0 |
| Bicarbonate | 0 | 0 |
| Bilirubin | 0 | 0 |
| Calcium, high | 0 | 0 |
| Calcium, low | 0 | 0 |
| Cholesterol | 0 | 0 |
| Creatine Kinase | 4 | 7 |
| Creatinine | 0 | 0 |
| Glucose, high | 0 | 0 |
| Glucose, low | 0 | 1 |
| LDL-cholesterol | 5 | 5 |
| LDL-cholesterol, fasting | 2 | 3 |
| LDL-cholesterol, not fasting | 3 | 2 |
| Lactate Dehydrogenase | 0 | 0 |
| Potassium, high | 2 | 0 |
| Potassium, low | 0 | 0 |
| Sodium, high | 0 | 0 |
| Sodium, low | 0 | 0 |
| Triglycerides | 3 | 2 |
| Triglycerides, fasting | 0 | 1 |
| Triglycerides, not fasting | 3 | 2 |
| Uric acid | 0 | 0 |
| Glomerular Filtration Rate, Estimated | 0 | 0 |
| Urine Glucose | 0 | 0 |
| Urine Protein | 0 | 0 |
Elevations of AST or ALT \> 3 x ULN concurrent with TBL \> 2 x ULN were defined as elevations on the same collection date. Participants must have had a non-missing AST, ALT, or TBL measurement in the OLE phase to be included.
| Percentage of participants | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Number of Participants With Elevations of AST or ALT > 3 x Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) > 2 x ULN During the DBT Phase | 0 (0.00 to 1.24) | 0 (0.00 to 1.24) |
Elevations of AST or ALT \> 3 x ULN concurrent with TBL \> 2 x ULN were defined as elevations on the same collection date. Participants must have had a non-missing AST, ALT, or TBL measurement in the DBT phase to be included.
| Percentage of participants | DBT Rimegepant/OL Rimegepant | DBT Placebo/OL Rimegepant |
|---|---|---|
| Percentage of Participants With Elevations of AST or ALT > 3 x ULN Concurrent With TBL > 2 x ULN During the OLE Phase | 0 (0.00 to 1.51) | 0 (0.00 to 1.52) |
Hepatic AEs were defined as all preferred terms in the DBT phase under the "Hepatic Disorders" Standardized Medical Dictionary (Version 21.1) for Regulatory Activities Query (SMQ), except those preferred terms in the "Congenital, Familial, Neonatal and Genetic Disorders of the Liver" SMQ.
| Participants | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Hepatic-related AE | 6 | 2 |
| Severe hepatic-related AE | 0 | 0 |
| Hepatic-related SAE | 0 | 0 |
| Hepatic-related AE leading to study drug discontinuation | 2 | 2 |
Hepatic AEs were defined as all preferred terms in the OLE phase under the "Hepatic Disorders" SMQ, except those preferred terms in the "Congenital, Familial, Neonatal and Genetic Disorders of the Liver" SMQ.
| Participants | DBT Rimegepant/OL Rimegepant | DBT Placebo/OL Rimegepant |
|---|---|---|
| Hepatic-related AE | 2 | 9 |
| Severe hepatic-related AE | 0 | 1 |
| Hepatic-related SAE | 0 | 0 |
| Hepatic-related AE leading to study drug discontinuation | 1 | 1 |
The Migraine Specific Quality of Life (MSQoL) is a self-administered, 14-item instrument that has been validated in 3 domains: role restriction, role prevention, and the emotional function. The role function-restrictive domain consists of 7 items that describe how migraine limits one's daily social and work-related activities. Participants respond to items using a 6-point scale: "none of the time," "a little bit of the time," "some of the time," "a good bit of the time," "most of the time," and "all of the time," which are assigned scores of 1 to 6, respectively. Item scores are recoded using (7 - original score). Next, raw dimension scores are computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life. The change from baseline was calculated as the MSQoL restrictive role function domain score at Week 12 of the DBT phase minus the MSQoL restrictive role function domain score at baseline.
| score on a scale | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Mean Change From Baseline in the Migraine Specific Quality of Life (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase | 18.0 (15.54 to 20.56) | 14.6 (12.07 to 17.10) |
The Migraine Disability Assessment (MIDAS) is a retrospective, self-administered, 5-item questionnaire that measures headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provide the number of missed work or school days; missed household chores days; missed social or leisure activity days; and days at work or school, and separately at home, where productivity was reduced by half or more in the last 3 months (scale: 0 - 90 for each of 5 subscales). The 5 subscale scores are summed to compute the MIDAS total score (scale: 0 - 450). Lower scores indicate less headache-related disability. The change from baseline was calculated as the MIDAS total score at Week 12 of the DBT phase minus the MIDAS total score at baseline.
| Scores on a scale | Rimegepant - Randomization Phase | Placebo - Randomization Phase |
|---|---|---|
| Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12 of the DBT Phase | -11.8 (-15.41 to -8.21) | -11.7 (-15.29 to -8.10) |
Collected over DBT Phase: From the first dose in the DBT Phase (Week 1) to Week 12 OLE Phase: Week 13 to Week 64 Follow-up phase: 8 weeks after the end of treatment (maximum duration of treatment: 64 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rimegepant - Randomization Phase | 0/370 (0%) | 3/370 (0.8%) | 0/370 (0%) |
| Placebo - Randomization Phase | 0/371 (0%) | 4/371 (1.1%) | 0/371 (0%) |
| DBT Rimegepant/OLE Rimegepant - OLE Phase | 1/302 (0.3%) | 7/302 (2.3%) | 41/302 (13.6%) |
| DBT Placebo/OLE Rimegepant - OLE Phase | 1/301 (0.3%) | 6/301 (2%) | 37/301 (12.3%) |
| DBT Rimegepant/OLE Rimegepant - Follow-up Phase | 0/332 (0%) | 2/332 (0.6%) | 41/332 (12.3%) |
| DBT Placebo/OLE Rimegepant - Follow-up Phase | 0/336 (0%) | 2/336 (0.6%) | 34/336 (10.1%) |
| Event | Rimegepant - Randomization Phase | Placebo - Randomization Phase | DBT Rimegepant/OLE Rimegepant - OLE Phase | DBT Placebo/OLE Rimegepant - OLE Phase | DBT Rimegepant/OLE Rimegepant - Follow-up Phase | DBT Placebo/OLE Rimegepant - Follow-up Phase |
|---|---|---|---|---|---|---|
| Abdominal pain lowerGastrointestinal disorders | 0/370 | 0/371 | 0/302 | 1/301 | 0/332 | 0/336 |
| ColitisGastrointestinal disorders | 0/370 | 0/371 | 0/302 | 1/301 | 0/332 | 0/336 |
| DiverticulitisInfections and infestations | 0/370 | 0/371 | 1/302 | 1/301 | 0/332 | 0/336 |
| Urinary tract infectionInfections and infestations | 0/370 | 0/371 | 0/302 | 1/301 | 0/332 | 0/336 |
| Myocardial infarctionCardiac disorders | 0/370 | 0/371 | 0/302 | 1/301 | 0/332 | 0/336 |
| Back painMusculoskeletal and connective tissue disorders | 0/370 | 0/371 | 0/302 | 1/301 | 0/332 | 0/336 |
| Aortic dissectionVascular disorders | 0/370 | 0/371 | 0/302 | 1/301 | 0/332 | 0/336 |
| Gastric ulcerGastrointestinal disorders | 0/370 | 0/371 | 1/302 | 0/301 | 0/332 | 0/336 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/370 | 0/371 | 1/302 | 0/301 | 0/332 | 0/336 |
| Septic shockInfections and infestations | 0/370 | 0/371 | 1/302 | 0/301 | 0/332 | 0/336 |
| Event | Rimegepant - Randomization Phase | Placebo - Randomization Phase | DBT Rimegepant/OLE Rimegepant - OLE Phase | DBT Placebo/OLE Rimegepant - OLE Phase | DBT Rimegepant/OLE Rimegepant - Follow-up Phase | DBT Placebo/OLE Rimegepant - Follow-up Phase |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/370 | 0/371 | 23/302 | 15/301 | 23/332 | 15/336 |
| Upper respiratory tract infectionInfections and infestations | 0/370 | 0/371 | 21/302 | 22/301 | 21/332 | 19/336 |
Participants who received at least one dose of study drug.
| Age, Continuous(years) | Rimegepant - Randomization Phase | Placebo - Randomization Phase | Total |
|---|---|---|---|
| Mean | 41.3 ± 13.01 | 41.1 ± 13.13 | 41.2 ± 13.06 |
| Sex: Female, Male(Participants) | Rimegepant - Randomization Phase | Placebo - Randomization Phase | Total |
|---|---|---|---|
| Female | 300 | 313 | 613 |
| Male | 70 | 58 | 128 |
| Ethnicity (NIH/OMB)(Participants) | Rimegepant - Randomization Phase | Placebo - Randomization Phase | Total |
|---|---|---|---|
| Hispanic or Latino | 105 | 98 | 203 |
| Not Hispanic or Latino | 265 | 273 | 538 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Rimegepant - Randomization Phase | Placebo - Randomization Phase | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 1 | 7 |
| Asian | 1 | 7 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 3 |
| Black or African American | 62 | 49 | 111 |
| White | 295 | 309 | 604 |
| More than one race | 6 | 2 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Dec 2019, 12 months.
Results were first posted in Aug 2021, 1 year 7 months after primary completion. A results delay was requested in Nov 2020.
Of 12 phase 2/3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant